Prostate stem cell antigen: A prospective therapeutic and diagnostic target

Cancer Letters

Volumn 277, Issue 2, 2009, Pages 126-132

  Raff, Adam B ^a   Gray, Andrew ^a   Kast, W Martin ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Immunotherapy; Prostate cancer; Prostate stem cell antigen

Indexed keywords

DENDRITIC CELL VACCINE; FLUTAMIDE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MESSENGER RNA; PROSTATE STEM CELL ANTIGEN;

ANTIGEN EXPRESSION; CANCER GROWTH; CANCER IMMUNIZATION; CARCINOGENESIS; CELL SURVIVAL; CHROMOSOME 8Q; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; GENE CONTROL; GENE LOCATION; GENE OVEREXPRESSION; GLEASON SCORE; HUMAN; IN SITU HYBRIDIZATION; LYMPHOCYTE PROLIFERATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN TARGETING; SHORT SURVEY; T LYMPHOCYTE ACTIVATION;

EID: 62749184977     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.08.034     Document Type: Review

References (54)

1. Jemal A., Siegal R., Ward E., Hao Y., Xu J., Murray T., and Thun M. Cancer statistics. CA Cancer J. Clin. 58 (2008) 71-96
2. Garnick M., and Fair W. Prostate cancer: emerging concepts: part I. Ann. Intern. Med. 125 (1996) 118-125
3. Crawford E.D., Rosenblum M., Ziada A., and Lange P.H. Overview: hormone refractory prostate cancer. Urology 54 (1999) 1-7
4. Tjoa B., and Murphy G. Progress in active specific immunotherapy of prostate cancer. Semin. Surg. Oncol. 18 (2000) 80-87
5. Reiter R.E., Gu Z., Watabe T., Thomas G., Szigeti K., Davis E., Wahl M., Nisitani S., Yamashiro J., Le Beau M., Loda M., and Witte O. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 95 (1998) 1735-1740
6. Ross S., Spencer S., Holcomb I., Tan C., Hongo J., Devaux B., Rangell L., Keller G., Schow P., Steeves R., Lutz R., Frantz G., Hillan K., Peale F., Tobin P., Eberhard D., Rubin M., Lasky L., and Koeppen H. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 62 (2002) 2546-2553
7. Gu Z., Thomas G., Yamashiro J., Shintaku P., Dorey F., Raitano A., Witte O., Said J.W., Loda M., and Reiter R.E. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19 (2000) 1288-1296
8. Han K., Seligson D., Liu X., Horvath S., Shintaku P., Thomas G., Said J.W., and Reiter R.E. Prostate stem cell antigen expression is associated with gleason score seminal vesicle invasion and capsular invasion in prostate cancer. J. Urol. 171 (2004) 1117-1121
9. Presky D., Low M., and Shevach E. Role of phosphatidylinositol-anchored proteins in T cell activation. J. Immunol. 144 (1990) 860-868
10. Rege T., and Hagood J. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim. Biophys. Acta 1763 (2006) 991-999
11. Witz I. Differential expression of genes by tumor cells of a low or a high malignancy phenotype: the case of murine and human Ly-6 proteins. J. Cell. Biochem. Suppl. 34 (2000) 61-66
12. Treister A., Sagi-Assif O., Meer M., Smorodinsky N., Anavi R., Golan I., Meshel T., Kahana O., Eshel R., Katz B.Z., Shevach E., and Witz I. Expression of Ly-6 a marker for highly malignant murine tumor cells is regulated by growth conditions and stress. Int. J. Cancer 77 (1998) 306-313
13. Malek T., Ortega G., Chan C., Kroczek R., and Shevach E. Role of Ly-6 in lymphocyte activation: induction of T cell activation by monoclonal anti-Ly-6 antibodies. J. Exp. Med. 164 (1986) 709-722
14. Eshel R., Zanin A., Sagi-Assif O., Meshel T., Smorodinsky N., Dwir O., Alon R., Brakenhoff R., van Dongen G., and Witz I. The GPI-linked Ly-6 antigen E48 regulates expression levels of FX enzyme and of E-selectin ligands on head and neck squamous carcinoma cells. J. Biol. Chem. 275 (2000) 12833-12840
15. Moore M.L., Teitell M.A., Kim Y., Watabe T., Reiter R.E., Witte O., and Dubey P. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate 68 (2008) 139-151
16. Cunha A.C., Weigle B., Kiessling A., Bachmann M., and Rieber E.P. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostate tissues. Cancer Lett. 236 (2006) 229-238
17. Ross S., Spencer S., Lasky L., and Koeppen H. Selective expression of murine prostate stem cell antigen in fetal and adult tissues and the transgenic adenocarcinoma of the mouse prostate model of prostate carcinogenesis. Am. J. Pathol. 158 (2001) 809-815
18. Watabe T., Lin M., Ide H., Donjacour A., Cunha G., Witte O., and Reiter R.E. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc. Natl. Acad. Sci. USA 99 (2002) 401-406
19. Dubey P., Wu H., Reiter R.E., and Witte O. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res. 61 (2001) 3256-3261
20. Lam J.S., Yamashiro J., Shintaku P., Vessella R.L., Jenkins R.B., Horvath S., Said J.W., and Reiter R.E. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin. Cancer Res. 11 (2005) 2591-2596
21. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W., Aspinall J., Cunha G., Donjacour A., Matusik R., and Rosen J. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92 (1995) 3439-3443
22. Gingrich J.R., Barrios R.J., Kattan M.W., Nahm H.S., Finegold M.J., and Greenberg N.M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 57 (1997) 4687-4691
23. Yang D., Holt G.E., Velders M.P., Kwon E.D., and Kast W.M. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res. 61 (2001) 5857-5860
24. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., Barrantes I.D.B., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., and Mak T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8 (1998) 1169-1178
25. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G., Li G., Roy-Burman P., Nelson P.S., Liu X., and Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 4 (2003) 209-221
26. Visakorpi T., Kallioniemi A.H., Syvanen A.C., Hyytinen E.R., Karhu R., Tammela T., Isola J.J., and Kallioniemi O.P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55 (1995) 342-347
27. Sato K., Qian J., Slezak J.M., Lieber M.M., Bostwick D.G., Bergstralh E.J., and Jenkins R.B. Clinical significance of alteration of chromosome 8 in high-grade advanced nonmetastatic prostate carcinoma. J. Natl. Cancer Inst. 91 (1999) 1574-1580
28. Jenkins R.B., Qian J., Lieber M.M., and Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostate carcinoma by fluorescence in situ hybridization. Cancer Res. 57 (1997) 524-531
29. Qian J., Bostwick D.G., Takahashi S., Borell T.J., Herath J.F., Lieber M.M., and Jenkins R.B. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. 55 (1995) 5408-5414
30. Jalkut M.W., and Reiter R.E. Role of prostate stem cell antigen in prostate cancer research. Curr. Opin. Urol. 12 (2002) 401-406
31. Argani P., Rosty C., Reiter R.E., Wilentz R.E., Murugesan S.R., Leach S.D., Ryu B., Skinner H.G., Goggins M., Jaffee E.M., Yeo C.J., Cameron J.L., Kern S.E., and Hruban R.H. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 61 (2001) 4320-4324
32. Iacobuzio-Donahue C.A., Maitra A., Shen-Ong G.L., Heek T.V., Ashfaq R., Meyer R., Walter K., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., and Hruban R.H. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am. J. Pathol. 160 (2002) 1239-1249
33. Wente M.N., Jain A., Kono E., Berberat P., Giese T., Reber H.A., Friess H., Bulcher M.W., Reiter R.E., and Hines O.J. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 31 (2005) 119-125
34. Elsamman E., Fukumori T., Kasai T., Nakatsuji H., Nishitani M.A., Toida K., Ali N., and Kanayama H.O. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. BJU Int. 97 (2006) 1202-1207
35. Amara N., Palapattu G., Schrage M., Gu Z., Thomas G., Dorey F., Said J.W., and Reiter R.E. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 61 (2001) 4660-4665
36. Elsamman E., Fukumori T., Tanimoto S., Nakanishi R., Takahashi M., Toida K., and Kanayama H.O. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int. 98 (2006) 668-673
37. The Study Group of Millennium Genome Project for Cancer. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 40 (2008) 730-740
38. Parekh D.J., Ankerst D.P., Troyer D., Srivastava S., and Thompson I.M. Biomarkers for prostate cancer detection. J. Urol. 178 (2007) 2252-2259
39. Hara N., Kasahara T., Kawasaki T., Bilim V., Obara K., Takahashi K., and Tomita Y. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin. Cancer Res. 8 (2002) 1794-1799
40. Zhigang Z., and Wenlu S. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate. Prostate 68 (2008) 190-199
41. Saffran D.C., Raitano A.B., Hubert R.S., Witte O., Reiter R.E., and Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl. Acad. Sci. USA 98 (2001) 2658-2662
42. Gu Z., Yamashiro J., Kono E., and Reiter R.E. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Cell 65 (2005) 9495-9500
43. Rosenberg S.A., and Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 5 (2004) 14639-14645
44. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., and Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
45. Morgenroth A., Cartellieri M., Schmitz M., Gunes S., Weigle B., Bachmann M., Abken H., Rieber E.P., and Temme A. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67 (2007) 1121-1131
46. Garcia-Hernandez M.D.L.L., Gray A., Hubby B., Klinger O.J., and Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 68 (2008) 861-869
47. Goldberg S.M., Bartido S.M., Gardner J.P., Guevara-Patino J.A., Montgomery S.C., Perales M.A., Maughen M.F., Dempsey J., Donovan G.P., Olson W.C., Houghton A.N., and Wolchok J.D. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin. Cancer Res. 11 (2005) 8114-8121
48. Waeckerle-Men Y., Uetz-von Allmen E., Fopp M., von Moos R., Bohme C., Schmid H., Ackermann D., Cerny T., Ludewig B., Groettrup M., and Gillessen S. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunother. 55 (2006) 1524-1533
49. Thomas-Kaskel A.K., Zeiser R., Jochim R., Robel C., Schultze-Seemann W., Waller C.F., and Veelken H. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J. Cancer 119 (2006) 2428-2434
50. Zhigang Z., and Wenlu S. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 65 (2005) 299-305
51. Zhigang Z., and Wenlu S. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer. Prostate 67 (2007) 653-660
52. Zhigang Z., and Wenlu S. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. Int. J. Cancer 122 (2008) 864-870
53. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3 (2002) 999-1005
54. Gray A., Raff A.B., Chiriva-Internati M., Chen S., and Kast W.M. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol. Rev. 222 (2008) 316-327